 |
 |

Gyrate Atrophy of the Choroid and RetinaLong-term Reduction of Ornithine Slows Retinal Degeneration
Muriel I. Kaiser-Kupfer, MD;
Rafael C. Caruso, MD;
David Valle, MD
Arch Ophthalmol. 1991;109(11):1539-1548.
Abstract
Gyrate atrophy of the choroid and retina is an autosomal recessive, chorioretinal dystrophy that begins in childhood and leads to blindness in the fourth to seventh decade of life. The primary defect is deficiency of ornithine- -amino-transferase, which results in accumulation of ornithine. We examined six pairs of affected siblings to determine if intrafamilial variability in the phenotype was less than interfamilial, and to determine if long-term (5- to 7-year) reduction of ornithine with an arginine-restricted diet had an effect on the progression of the chorioretinal degeneration. All but one set of siblings underwent periodic ophthalmologic examinations. The clinical diagnosis was confirmed with the demonstration of hyperornithinemia and deficiency of ornithine- -aminotransferase. The molecular defects in their ornithine- -amino-transferase genes also were determined. The two younger pairs of siblings were given an arginine-restricted diet and followed up for 5 to 7 years. We found strikingly similar phenotypes in affected members of the same pair of siblings. In the young patients receiving the diet, there was substantial reduction of ornithine levels. These children had only modest progression of their ocular disease during this period. Furthermore, a comparison of the outcome of the younger with their older siblings at an equivalent age showed that the younger siblings, who started receiving the diet at an earlier age, had much less ocular disease. We conclude that intrafamilial phenotypic variation in gyrate atrophy is less than interfamilial and, therefore, that genetic heterogeneity plays a role in the phenotypic variability of gyrate atrophy. Furthermore, we conclude that chronic reduction of ornithine with an arginine-restricted diet dramatically slows the progression of the chorioretinal dystrophy.
Author Affiliations
From the National Eye Institute, National Institutes of Health, Bethesda, Md (Drs Kaiser-Kupfer and Caruso), and The Howard Hughes Medical Institute Laboratory of Genetics, The Johns Hopkins University School of Medicine, Baltimore, Md (Dr Valle).
Footnotes
Accepted for publication July 30, 1991.
Reprint requests to National Eye Institute, National Institutes of Health, 9000 Rockville Pike, 10/10N226, Bethesda, MD 20892 (Dr Kaiser-Kupfer).
CiteULike Connotea Delicious Digg Facebook Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Induction of Arginase II mRNA by Nitric Oxide Using an In Vitro Model of Gyrate Atrophy of Choroid and Retina
Ohnaka et al.
IOVS 2011;52:1493-1500.
ABSTRACT
| FULL TEXT
First reported cases of gyrate atrophy of the choroid from Nepal
Shrestha et al.
BMJ Case Reports 2010;2010:bcr0420102951-bcr0420102951.
ABSTRACT
| FULL TEXT
Polyamines upregulate the mRNA expression of cationic amino acid transporter-1 in human retinal pigment epithelial cells
Kaneko et al.
Am. J. Physiol. Cell Physiol. 2007;293:C729-C737.
ABSTRACT
| FULL TEXT
Use of an Arginine-Restricted Diet to Slow Progression of Visual Loss in Patients With Gyrate Atrophy
Kaiser-Kupfer et al.
Arch Ophthalmol 2004;122:982-984.
ABSTRACT
| FULL TEXT
Peripheral nervous system in gyrate atrophy of the choroid and retina with hyperornithinemia
Peltola et al.
Neurology 2002;59:735-740.
ABSTRACT
| FULL TEXT
Gyrate Atrophy of the Choroid and Retina: Further Experience With Long-term Reduction of Ornithine Levels in Children
Kaiser-Kupfer et al.
Arch Ophthalmol 2002;120:146-153.
ABSTRACT
| FULL TEXT
Assessment of Visual Function in Patients With Gyrate Atrophy Who Are Considered Candidates for Gene Replacement
Caruso et al.
Arch Ophthalmol 2001;119:667-669.
ABSTRACT
| FULL TEXT
Correction of ornithine accumulation prevents retinal degeneration in a mouse model of gyrate atrophy of the choroid and retina
Wang et al.
Proc. Natl. Acad. Sci. USA 2000;97:1224-1229.
ABSTRACT
| FULL TEXT
Ocular Gene Therapy: From Fantasy to Foreseeable Reality
Zack
Arch Ophthalmol 1993;111:1477-1479.
ABSTRACT
|